Immunomedics, inc. (IMMU)
CashFlow / Yearly
Dec'19Jun'18Jun'17Jun'16Jun'15Jun'14Jun'13Jun'12Jun'11Jun'10
Cash flows from operating activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

-357,319

-273,887

-153,266

-59,136

-48,123

-35,531

-11,486

1,264

-14,412

36,996

Adjustments to reconcile net loss to net cash used in operating activities:
Changes in fair value of warrant liabilities

0

108,636

61,074

0

-

-

-

-

-

-

Warrant related expense

0

0

7,649

0

-

-

-

-

-

-

Depreciation and amortization

3,800

1,300

900

738

578

569

1,036

1,496

1,477

1,436

Loss on disposal of property and equipment

-1,003

0

0

-

-

-

-

-

-

-

Gain on insurance claim for equipment failure

-

-

-

-

-

-

137

-

279

-

Amortization of discounts of auction rate securities

-

-

-

-

-

-

-

-

120

466

Gain on sales/redemptions of auction rate securities securities

-

-

-

-

-

-

-

-

454

915

Accounts receivable, net

295

-452

-103

190

-271

-62

-66

-54

288

-354

Inventories - net of reserve

-

-

-

-256

-

-

-

-

-

-

Inventories, net

0

-580

196

-620

-328

204

617

126

-245

901

Other receivables

0

30

-223

-98

553

-130

238

-

-

-362

Prepaid expenses and other current assets

16,423

7,679

97

-

-

-

-

-

-

-

Other current assets

-

-

-

-762

-478

-1,182

-149

-

-

73

Accounts payable and accrued expenses

-

-

-

-3,146

776

1,450

598

-491

748

-66

Accounts payable and accrued expenses

29,977

-1,518

15,809

-

4,946

2,935

966

-501

410

-322

Other liabilities

-186

0

0

-

-

-

-

166

155

106

Interest on non-recourse debt

39,929

19,791

0

0

-

-

-

-

-

-

Loss on induced exchanges of debt

0

13,005

0

0

-

-

-

-

-

-

Amortization of deferred revenue

0

77

64

36

5

2,674

176

128

118

-45,685

Amortization of bond premiums

0

-31

-218

-670

-544

-228

-

-

-

-

Amortization of debt issuance costs

50

1,679

730

730

281

-

-

-

-

-

Non-cash lease expense

264

0

0

-

-

-

-

-

-

-

Amortization of deferred rent

0

-279

-10

-100

99

99

99

-

-

-

Loss on sale of marketable securities

0

0

-16

2

11

7

-

-

-

-

Decrease in allowance for doubtful accounts

0

-9

-62

20

-34

39

-5

22

-20

-81

Other

-

-

-

-

-

-

-

-

-

-297

Inventory reserve

-

-

-

-

-

-

-

-

-

600

Non-cash expense related to stock-based compensation

11,736

4,024

4,333

3,741

2,788

3,218

2,265

2,059

1,966

1,808

Non-cash decrease in value of life insurance policy

-

-

-

-21

-155

18

-3

-

-

56

Non-cash financing expenses

0

0

347

0

-

-

-

-

-

-

Deferred revenue

65,000

0

0

-

37

134

2,774

108

0

-

Net cash used in operating activities

-222,442

-133,426

-62,250

-48,462

-38,996

-30,690

-5,899

4,908

-12,186

-7,068

Cash flows from investing activities
Purchases of marketable securities

0

10,380

131,610

2,749

86,307

44,116

-

-

-

-

Proceeds from sales/maturities of marketable securities

0

95,112

57,183

50,850

34,491

9,024

-

-

-

-

Purchases of property and equipment

6,849

9,975

1,837

2,226

924

378

595

568

605

684

Proceeds from sales and redemptions of auction rate securities

-

-

-

-

-

-

-

-

9,545

9,870

Net cash used in investing activities

-6,849

74,757

-76,264

45,875

-52,740

-35,069

-457

-568

9,218

9,185

Cash flows from financing activities:
Proceeds from partial liquidation of life insurance policy

-

-

-

-

-

400

-

-

-

-

Proceeds from insurance claim for equipment failure

-

-

-

-

-

-

137

-

279

-

Proceeds from issuance of convertible senior notes

-

-

-

-

100,000

-

-

-

-

-

Payment of debt issuance costs

-

-

-

-

3,657

-

-

-

-

-

Exercise of stock options, net

2,553

2,261

4,290

2,733

2,959

1,799

266

171

243

25

Exercise of warrants

0

78,226

0

-

-

-

-

-

-

-

Sale of preferred stock, net of related expenses

0

0

121,782

0

-

-

-

-

-

-

Proceeds from public offering of common stock

273,031

299,467

28,578

0

-

-

-

-

-

-

Proceeds from the issuance of non-recourse debt

0

182,216

0

0

-

-

-

-

-

-

Debt conversion fees

0

530

0

0

-

-

-

-

-

-

Tax withholding payments for stock-based compensation

0

1,521

546

369

585

331

246

98

-

-

Payments for stock plan activity

-

-

-

-

-

-

-

-

96

-

Share purchases of majority-owned subsidiary

-

-

-

-

-

-

39

-

0

-

Issuance of common stock purchase warrant

-

-

-

-

-

-

-

1,582

0

-

Net cash provided by financing activities

347,181

627,903

168,804

2,364

98,716

31,277

14,765

1,655

147

25

Effect of changes in exchange rates on cash, cash equivalents and restricted cash

-22

-46

-100

-26

-489

118

79

-255

384

-

Net decrease in cash, cash equivalents and restricted cash

117,868

569,188

30,190

-249

6,491

-34,364

8,487

5,740

-2,435

2,142

Supplemental disclosure of cash flow information:
Interest paid

338

2,850

4,750

4,803

-

-

-

-

-

-

Income taxes paid

0

0

24

29

75

136

135

23

441

658

Schedule for non-cash investing and financing activities:
Issuance of common shares for debt conversion

0

92,307

0

0

-

-

-

-

-

-

Accrued capital expenditures

101

2,173

0

0

-

-

-

-

-

-

Non-cash component of warrant exercise

0

0

0

0

-

-

-

-

-

-

Shares received in cashless exercise

1,271

0

0

0

-

-

-

-

-

-

Market Offering
Proceeds from private offering of common stock

71,597

0

0

0

-

29,809

14,785

-

0

-

Private placement
Proceeds from private offering of common stock

0

67,784

14,700

-

-

-

-

-

-

-